Arovella Therapeutics Limited (ASX:ALA)

Australia · Delayed Price · Currency is AUD

0.0800

-0.0050 (-5.88%)

Apr 29, 2026, 2:35 PM AEST

-11.11% (1Y)

Market Cap	102.75M
Revenue (ttm)	3.21M
Net Income (ttm)	-7.93M
Shares Out	1.21B
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	681,502
Average Volume	990,326
Open	0.0840
Previous Close	0.0850
Day's Range	0.0800 - 0.0840
52-Week Range	0.0650 - 0.1250
Beta	-0.00
RSI	54.98
Earnings Date	Apr 17, 2026

About Arovella Therapeutics

Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly know... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1999

Employees 27

Stock Exchange Australian Securities Exchange

Ticker Symbol ALA

Full Company Profile

Financial Performance

In fiscal year 2025, Arovella Therapeutics's revenue was 3.44 million, an increase of 76.22% compared to the previous year's 1.95 million. Losses were -7.51 million, -14.14% less than in 2024.

Financial Statements

News

Arovella Therapeutics Transcript: AGM 2025

The meeting highlighted strong financial positioning, major progress toward clinical trials for lead asset ALA-101, and strategic pipeline expansion into solid tumors. Leadership transitions and new hires were announced, with confidence in overcoming sector challenges and regulatory milestones.

6 months ago - Transcripts

Arovella Therapeutics Transcript: EGM 2025

The meeting addressed two resolutions related to the March 2025 placement, with voting conducted by poll and results to be released on ASX. Shareholders' questions focused on webcast access and meeting formats, with future meetings planned as hybrid or in-person.

1 year ago - Transcripts

Arovella Therapeutics Earnings Call Transcript: Q3 2025

Lead iNKT cell therapy ALA-101 is on track for phase I trials in 2025, supported by a strong cash position and recent capital raise. Expansion into solid tumors with CLDN18.2 and IL-12-TM armoring is progressing, with key preclinical and manufacturing milestones achieved.

1 year ago - Transcripts